Physician profile
Janine Hepler
NPI 1528424082
$3,524.28
in general payments reported to CMS, 2019-2025
34 companies · $838 in 2025
The $838 reported for 2025 was more than what 84% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $566 · 2022: $551 · 2023: $942 · 2024: $627 · 2025: $838.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,407.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $595.93 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $575.94 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $569.69 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $382.13 | 2021-2025 | Jardiance, Stiolto Respimat, Combivent Respimat |
| Abbvie INC. | $354.87 | 2021-2025 | |
| Exact Sciences Corporation | $121.24 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $106.42 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $101.60 | 2021-2024 | Trintellix |
| Becton, Dickinson and Company | $94.94 | 2025 | Venclose Maven Catheter |
| Otsuka America Pharmaceutical, INC. | $63.38 | 2023-2024 | Nuedexta, Rexulti |
| Idorsia Pharmaceuticals US INC | $60.06 | 2022-2023 | Quviviq |
| Daiichi Sankyo INC. | $47.30 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $37.82 | 2023 | Gvoke Hypopen |
| Pfizer INC. | $37.43 | 2021-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $37.32 | 2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $28.52 | 2022-2025 | Contrave |
| Organon LLC | $26.08 | 2023 | Nexplanon |
| Ani Pharmaceuticals, INC. | $22.29 | 2025 | Purified Cortrophin Gel |
| Bard Peripheral Vascular, INC. | $21.03 | 2025 | Venclose Maven Catheter |
| Seqirus USA INC | $19.42 | 2025 | Flucelvax, Fluad |
| Bayer Healthcare Pharmaceuticals INC. | $19.17 | 2022 | |
| Abbott Laboratories | $18.47 | 2023 | Freestyle Libre 3 |
| Insulet Corporation | $17.82 | 2025 | Omnipod |
| Axsome Therapeutics, INC. | $17.36 | 2024 | Auvelity |
| Novartis Pharmaceuticals Corporation | $17.05 | 2021 | |
| Therapeuticsmd, INC. | $16.79 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $16.10 | 2021 | |
| Shield Therapeutics INC | $15.89 | 2025 | |
| Amarin Pharma, INC. | $15.16 | 2021 | |
| Exeltis, USA INC. | $14.35 | 2022 | |
| Merck Sharp & Dohme LLC | $14.28 | 2022 | |
| Janssen Pharmaceuticals, INC | $14.20 | 2021 | |
| Esperion Therapeutics, INC. | $13.97 | 2025 | Nexletol |
| Phathom Pharmaceuticals, INC. | $10.26 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janine Hepler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.